Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001213900-25-004060
Filing Date
2025-01-16
Accepted
2025-01-16 10:40:28
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10825
2 AGREEMENT OF JOINT FILING ea022788001ex-1_kazia.htm EX-1 4537
  Complete submission text file 0001213900-25-004060.txt   17196
Mailing Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 2000
Business Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 2000 01161298780088
KAZIA THERAPEUTICS LTD (Subject) CIK: 0001075880 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: SCHEDULE 13G | Act: 34 | File No.: 005-50612 | Film No.: 25534633
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 405 LEXINGTON AVE. 9TH FLOOR NEW YORK NY 10174
Business Address 405 LEXINGTON AVE. 9TH FLOOR NEW YORK NY 10174 (818) 438-9794
Alumni Capital LP (Filed by) CIK: 0001912606 (see all company filings)

EIN.: 873893017 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G